Attached files
| file | filename |
|---|---|
| EX-32.2 - EXHIBIT 32.2 - Tempest Therapeutics, Inc. | q42017ovas-20171231xex322.htm |
| EX-31.2 - EXHIBIT 31.2 - Tempest Therapeutics, Inc. | q42017ovas-20171231xex312.htm |
| EX-31.1 - EXHIBIT 31.1 - Tempest Therapeutics, Inc. | q42017ovas-20171231xex311.htm |
| EX-23.1 - EXHIBIT 23.1 - Tempest Therapeutics, Inc. | q42017exhibit231.htm |
| EX-21.1 - EXHIBIT 21.1 - Tempest Therapeutics, Inc. | q42017exhibit211.htm |
| EX-10.36 - EXHIBIT 10.36 - Tempest Therapeutics, Inc. | exhibit1036-lilleofferlett.htm |
| EX-10.15 - EXHIBIT 10.15 - Tempest Therapeutics, Inc. | q42017exhibit1015.htm |
| 10-K - 10-K - Tempest Therapeutics, Inc. | ovas-20171231x10k.htm |
EXHIBIT 32.1
Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002, by Executive Chair
In connection with the Annual Report on Form 10-K of OvaScience, Inc. (the "Company") for the period ended December 31, 2017, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned, Christopher Kroeger, M.D., M.B.A., as Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that:
(1)the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: March 15, 2018
By: | /s/ CHRISTOPHER KROEGER |
Christopher Kroeger, M.D., M.B.A. | |
Chief Executive Officer | |
(Principal executive officer) | |